Home - Ionis Pharmaceuticals

News

December 6, 2018

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 DataMore »

November 27, 2018

First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual MeetingMore »

November 13, 2018

Ionis Pharmaceuticals to Present at Jefferies 2018 London Healthcare ConferenceMore »

November 12, 2018

Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific SessionsMore »

Latest Updates

#ICYMI Listen to the recorded #IonisInvestorDay2018 webcast and hear how Ionis continues to innovate and deliver once-in-a-lifetime breakthroughs for patients. Link: https://t.co/M5oZ3MEMLg $IONS #RNA #innovation #scienceandtechnology #biotechnology #pharmaceuticals

We continue to broaden the utility of our #antisense #technology & its potential to deliver transformative medicines to patients. Read more about our work in @endpts https://t.co/WoDpZJ0XTw $IONS #RNA #innovation

Clinical Trials

We have numerous ongoing clinical trials designed to evaluate our drugs in a variety of health conditions. More »

News

Events

Latest Updates

Clinical Trials